Phase II open-label, multi-center study of CP-547, 632, an oral tyrosine kinase inhibitor of VEGFR-2, in subjects with recurrent or persistent small-volume epithelial ovarian cancer, primary peritoneal serous cancer, or fallopian tube cancer
Phase of Trial: Phase II
Latest Information Update: 15 Aug 2014
At a glance
- Drugs PAN 90806 (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 26 Apr 2007 New trial record.